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The longitudinal pattern of lung function in children with sickle cell anemia (SCA) has 
shown a decrease in FEV1 % predicted, a risk factor for death in adults with SCA, but predictors 
for this decline are poorly characterized. In a prospective longitudinal multi-center cohort of 
children with SCA, we tested the hypotheses that: 1) FEV1 % predicted declines over time; and 
2) SCA-specific characteristics and therapy predict this decline. At three clinical centers, 
children with SCA (HbSS or HbSβ0 thalassemia), unselected for respiratory disease, were 
enrolled in the Sleep and Asthma Cohort (SAC) study. Study-certified pulmonary function 
technicians performed spirometry and lung volumes. Each assessment was reviewed centrally. 
Predicted values were determined for TLC, FEV1, FVC, and FEV1/FVC ratio. A total of 197 
participants, mean age 11.0 years at first testing (range 4-19.3 years), had a minimum of three 
spirometry measurements an average of 4.4 years (range 1.08-6.5 years) from baseline to 
endpoint. In a multivariable model, FEV1 % predicted declines by 0.3% for every additional year 
of age (95% CI -0.56 - -0.05, p=0.020). Sex, asthma history, hemoglobin, reticulocyte count, 
white blood cell count, incidence rate of severe acute pain and acute chest syndrome episodes, 
and hydroxyurea therapy were not associated with a decline in FEV1 % predicted. In a large 
rigorously evaluated, prospective cohort of an unselected group of children with SCA, FEV1 % 
predicted declines minimally over an average of 4 years, and none of the examined disease 







Pulmonary abnormalities are being increasingly recognized as a significant cause of 
morbidity and mortality in sickle cell anemia (SCA), including acute chest syndrome (ACS), 
asthma, recurrent wheezing, sleep disordered breathing, dyspnea, and pulmonary hypertension. 
Improved childhood survival has resulted in increased recognition of chronic lung disease in 
older patients with SCA. Studies are now beginning to explore the impact of pulmonary 
complications on lung function for adults and children with SCA.1 While most children with 
SCA have lung function that is within normal limits,2,3 lung growth is significantly reduced 
compared to age and race matched controls.4  By adulthood, restrictive defects are commonly 
reported.5,6 However, few studies have prospectively evaluated the longitudinal trajectory of lung 
function in children with SCA. 
Decreased FEV1 % predicted has been associated with an increased risk for earlier death 
in the general population 7–9 and in individuals with cystic fibrosis.10,11 Similarly, longitudinal 
data from the Cooperative Study of Sickle Cell disease showed that adults with SCA who had a 
decrease in expiratory volume in 1 second (FEV1) died earlier over the course of five years 
compared to those who did not.12 Only three studies have been performed in children with SCA 
to understand what factors, if any, contribute to a longitudinal decline in FEV1 % predicted. The 
three prior studies, two retrospective and one prospective, have shown variability in the 
magnitude of FEV1 % predicted decline over time (0.9-3.3% per year) 
13–15 leading to difficulty 
for providers in interpreting this change.  
None of the previous studies have accounted for intra-individual variability of the test 
results using the coefficient of variation (CV), which gives an estimation of the expected 
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participant biological and instrument variability.16 We tested the hypothesis that children with 
SCA have a decline in FEV1 % predicted and SCA-specific characteristics, treatment with 
hydroxyurea, or both, predict a decline in FEV1 % predicted. We also sought to interpret any 
observable change in lung function relative to a calculated age-based CV for children with SCA.  
Methods 
Study design and recruitment  
The Sleep and Asthma Cohort (SAC) is a prospective cohort study of children and 
adolescents with SCA, unselected for respiratory disease. Participants ranged from 4 to 18 years 
of age and were enrolled and followed between 2005 and 2011 at three clinical centers: 
Washington University School of Medicine in St. Louis, Missouri; Case Western Reserve 
University in Cleveland, Ohio; and UCL Great Ormond Street Institute of Child Health in 
London, UK (which recruited from three London hospitals). Institutional review boards for each 
site approved the study protocol. Participants were either homozygous for sickle cell hemoglobin 
[HbSS (N=240)] or compound heterozygous for sickle β thalassemia zero [HbSβ0 (N=12)]. 
Children were not eligible for participation in the study if they received long term blood 
transfusion therapy, received overnight oxygen or continuous positive airway pressure (CPAP) 
support, had chronic lung disease other than asthma (such as sarcoidosis), or were known to be 
human immune deficiency virus (HIV) positive. After the start of the study, data from 
participants initiated on chronic blood transfusion therapy were censored from this point forward 
due to the known decrease in pain events following initiation of chronic transfusion therapy. 
Parents provided written informed consent for all participants and patients provided assent when 
appropriate. Full manual of operations for the study design can be provided upon request.  
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Pulmonary Function Testing 
Pulmonary function tests were obtained when participants were at least 4 weeks after 
discharge from the hospital for SCA complications and at baseline health without current illness, 
pain, or acute respiratory symptoms. Pulmonary function testing (spirometry and body 
plethysmography) was done at study enrollment and then at least annually during the study 
period. Total number of pulmonary function tests was highly dependent on participants’ ability 
to perform the test with adequate quality control measures. Spirometry was performed using best 
maximal effort as selected by study certified pulmonary function technicians using a 
pneumotachograph-type spirometer interfaced with a personal computer system (Jaeger 
MasterScope; VIASYS, Hoechberg, Germany) as described in detail by Field.17 Spirometry was 
performed at least 4 hours after the use of a short-acting bronchodilator and 12 hours after use of 
a long-acting bronchodilator according to ATS standards for children.18,19 Measures obtained and 
validated through rigorous quality control include FEV1 and forced vital capacity (FVC). Static 
lung volume measurements were performed at the time of spirometry measurements using a 
Jaeger MasterScreen (Cleveland and London) or Sensor Medics VMAX (St. Louis) 
plethysmograph per ATS/ European Respiratory Society (ERS) standards.20 Results for 
spirometry and lung volumes from all three centers were over-read by a senior technician to 
ensure that results were valid. 
Abnormal lung function definition  
Predicted values were determined for each participant based on their age, sex, height, and 
race for FEV1, FVC, and FEV1/FVC ratio using the Global Lung Function 2012 multi-ethnic 
reference equations (GLI).21,22 Abnormal results for FEV1, FVC, and FEV1/FVC ratio were 
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determined by comparison to their lower limits of normal (LLN) defined with a cut-off at the 5th 
percentile (LLN 5%, z-score −1.64).21 Reference equations for TLC were used 23 with an 
African-American adjustment of 12%.24 Participants were categorized with a restrictive 
abnormality if their TLC was less than 80% predicted per ATS/ERS recommendations 25 with a 
normal FEV1/FVC, an obstructive abnormality if their FEV1/FVC was less than LLN, and a 
mixed pattern if both TLC and FEV1/FVC were less than the LLN.
25 Nonspecific pattern was 
defined as reduced FEV1 and/or FVC with a normal FEV1/FVC and normal TLC.
26,27 
Clinical Covariates  
Postulated covariates were selected due to their proposed impact on lung disease in 
children with SCA and included: age at enrollment, sex, baseline hemoglobin level, baseline 
white blood cell count, baseline reticulocyte count, incidence rates of acute pain or ACS 
episodes, treatment with hydroxyurea at baseline and throughout the study, and a history of 
asthma.28 Asthma was defined as a clinical diagnosis made by a physician coupled with current 
use of asthma medication.29 ACS was defined as a new clinical or radiographic pulmonary 
infiltrate in the context of an acute illness characterized by respiratory symptoms (cough, 
wheezing, rales, chest pain, decreased oxygen saturation (>2%) from baseline, use of accessory 
muscles of respiration, or increased respiratory rate) with or without fever.  Pneumonia was 
included in this definition. An acute pain episode was defined as a hospitalization for SCA-
associated pain, excluding headaches, and requiring opioid treatment. All ACS and pain episodes 
in the first three years of the study were reviewed by a single investigator at each participating 
site with over-reading by the principal investigator (M.R.D), to ensure uniform definitions of 
ACS and pain in this multi-center study. 
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Coefficient of Variation  
 A separate sub-analysis to calculate the CV was performed. Participants with 2 
spirometry measurements within a 6-month window were included in the sub-analysis. The CV 
was calculated from these paired spirometry measurements for FEV1 % predicted, FVC % 
predicted, and FEV1/FVC % predicted. For the group of paired measurements, the CV is the ratio 
of the standard deviation (SD) of the mean to the mean value of all measurements. The CV was 
calculated separately for paired measurements in participants below and above 16 years of age. 
We selected to have two separate CV for older and younger participants to allow for anticipated 
improvement in reproducible spirometry technique when comparing the effort of a 4 year old 
compared to a 16 year old. 
Comparison to adult cohort of participants with SCA 
To predict if children in our cohort would have a rate of decline in FEV1 % predicted 
comparable to what has been observed in adults with SCA, we included original data from two 
adult SCA cohorts. The Cooperative Study of Sickle Cell Disease (CSSCD) included physical 
examinations with spirometry evaluations from March 6, 1979 to August 13, 1993.30 We also 
analyzed a more contemporary cohort of adults with SCA followed at the Vanderbilt-Meharry 
Center for Excellence in Sickle Cell Disease in Nashville, TN from January 1, 2003 to January 
31, 2016. Methods for data collection of the Vanderbilt-Meharry cohort are described in detail as 
per Chaturvedi et al.31  
Statistical Analysis  
Descriptive statistics are presented for demographic and clinical factors. A multivariable 
mixed model regression analysis was used to predict change over time in three spirometry 
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parameter outcomes (FEV1 % predicted, FVC % predicted, and FEV1/FVC % predicted) with a 
pre-specified set of covariates. Hydroxyurea use was measured as a time varying covariate. 
Therefore, if an individual was started on hydroxyurea after first spirometry, the change in the 
remainder of their spirometry values would be analyzed including hydroxyurea use as a 
covariate. The mixed model approach was chosen to allow longitudinal data for participants to 
be combined into a single model while taking into account intra-individual correlations in 
spirometry values. As per mixed model analysis, participants with missing data on a covariate 
are not excluded, and participants can have different numbers of spirometry measures. The 
models also allow for both random intercepts and slopes to assess the effect of age, which allow 
each participant to have their own intercept, slope, or both. The CV was calculated for 
spirometry measurements within six months. The CV was then compared to actual change in 
each lung function parameter for each participant. Analyses were conducted using IBM SPSS 
Statistics (Version 24, Armonk, NY, IBM).  
Results  
Demographics  
 A total of 223 participants were enrolled and had spirometry measurements performed. 
Of these participants, 197 were eligible for the primary analysis as they had at least three (range 
3-8) spirometry measurements performed over a minimum follow up of 1 year (range 1.1-6.5 
years). The only statistical differences in demographic features were in age, as the excluded 
group were younger (median 8.8 years versus 10.7 years). The only differences in 16 baseline 
clinical or laboratory features were the excluded group had a higher proportion of bronchodilator 
response to albuterol and a slightly lower baseline FEV1 % predicted (mean 82.82 versus 88.48), 
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Supplemental Table 1. Mean age of our final cohort at first testing was 11.0 years (range 4-19.3 
years). Table 1 shows descriptive statistics of the final sample. Supplemental Figure 1 provides a 
schematic of our study design.   
Age is the only covariate predictive of a significant decline in FEV1 % predicted 
The multivariable linear regression mixed model demonstrated that FEV1 % predicted 
declines by 0.3% per year (95% CI -0.56, -0.05, p=0.02). Other than age, no postulated risk 
factors were associated with a decline in FEV1 % predicted over time (Table 2 and Figure 1). We 
directly tested the effect of duration of follow-up on decline in FEV1 % predicted by substituting 
that variable for age, and adding baseline age, but follow-up time was not significant (p=0.49). 
Age was not significantly associated with change in FVC % predicted (-0.20% per year, CI -0.45 
- 0.06, p=0.13). In the multivariable model, no covariates were associated with a change in 
FEV1/FVC % predicted over time, including age (-0.07% per year, 95% CI -0.21- 0.08, p=0.35). 
In the multivariable model, any hydroxyurea use (at baseline and/or throughout the study) was 
associated with a higher FVC % predicted using time varying covariates (2.02% per year, 95% 
CI 0.04 - 4.0, p=0.05). Results are summarized in Table 2 and Figure 1.  
Calculated coefficient of variation was lower in children greater than 16 years of age  
From the 197 participants in the analysis, 142 were included in the analysis to calculate 
the coefficients of variation for FEV1 % predicted, FVC % predicted, and FEV1/FVC % 
predicted as they had at least two spirometry measurements completed less than 6 months apart 
(Supplemental Figure 1). Among 142 participants, 116 pairs were analyzed before age 16 and 26 
pairs at age 16 or later. The CV was calculated separately within each age subgroup to allow for 
change as participants age, as previous data has demonstrated an increase in variability in 
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spirometry measurements in younger children as compared to older adults and adolescents.32 The 
mean time period between paired measurements was 5.4 months. Calculated CV for FEV1 % 
predicted before age 16 was 7.32% and 4.46% after age 16 and for other spirometry values with 
95% confidence intervals listed in Supplemental Table 2.  
Majority of participants did not have decline in spirometry values greater than coefficient of 
variation  
To apply the CV to the individual change in our cohort of 197 participants, we used the 
age of the first spirometry (below or above/equal to 16 years of age) to determine which CV to 
use. We found that the majority of our cohort did not demonstrate a decline on any lung function 
parameter greater than the calculated CV (N=100, 50.8%). Fifty three participants (26.9%) had a 
decrease in FEV1 % predicted greater than the calculated CV while 51 participants (25.9%) 
showed an increase in FEV1 % predicted greater than the calculated CV. Supplemental Table 2 
describes the number of participants with a decline in lung function greater than the CV for each 
spirometry parameter. Supplemental Figure 2 provides examples of the change in FEV1 % 
predicted for several patients to demonstrate the observed variation.    
Higher baseline spirometry measurements are associated with a decrease in FEV1, FVC, 
FEV1/FVC % predicted values that are greater than the CV 
Multivariable logistic regression models demonstrate that a larger baseline FEV1 % 
predicted was associated with a higher odds of having a decline in FEV1 % predicted that 
exceeds the CV (OR 1.06, 95% CI 1.03 - 1.09, p<0.001), such that those participants beginning 
with a 1% higher FEV1 at baseline were 6% more likely to have a decline in FEV1 % predicted 
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that exceeds the CV. None of the other assessed covariates were associated with a decrease in 
FEV1 % predicted. 
Similarly, only baseline FVC % predicted is associated with a larger decrease in FVC % 
predicted (OR 1.06, 95% CI 1.03-1.09, p<0.001). None of the other assessed covariates are 
associated with a decrease in FVC % predicted greater than the CV. Baseline FEV1/FVC % 
predicted is associated with a decline in FEV1/FVC % predicted greater than the CV (OR 1.18, 
95% CI 1.10-1.26, p<0.001). Age also had a negative relationship to a decrease in FEV1/FVC % 
predicted (OR 0.89, 95% CI 0.81 – 0.98, p=0.012), such that participants who are younger at 
baseline were more likely to have a decline in the FEV1/FVC % predicted greater than the CV.   
Baseline lung function pattern is not associated with future lung function pattern  
Participants in our cohort did not demonstrate a consistent change in lung function 
pattern over time. A total of 81 participants had complete spirometry and TLC data available for 
categorization of lung function category at baseline and endpoint. Participants with complete 
TLC data were noted to be older at first spirometry measurement (mean age 12.7 years vs 9.6 
years, p<0.001), and had longer prospective follow up (mean 4.6 years vs 3.8 years, p<0.001). 
The majority of the participants (N= 47, 58.0%) started the study with normal lung function and 
ended with study with normal lung function. Results are summarized in Supplemental Table 3. 
Discordance between predicted and observed decline in FEV1 % in children and adults with SCA 
In the CSSCD adult cohort, 430 participants had a mean age of 32.6 years, with a mean 
FEV1 % predicted of 77.4%.
33 In the more contemporary adult SCA cohort, 197 adults with a 
mean age of 31.8 years, demonstrated a mean FEV1 % predicted of 77.2%.
31  If we extrapolate 
the predicted decline in FEV1 % predicted  of 0.3% per year in the SAC cohort, starting with an 
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11 year old participant, 19 years later (by 32 years of age) the predicted mean FEV1 % predicted 
would be 88%. This extrapolated result is discordant with the observed FEV1 % predicted of 
77% measured in both CSSCD and the Vanderbilt –Meharry Sickle Cell Disease Center adult 
cohorts (Figure 2). 
Discussion   
In a large prospective, rigorously evaluated study of 197 children with SCA who had 
undergone a minimum of three spirometry measurements over an average of 4.4 years, we have 
demonstrated that children have a very small decline in FEV1 % predicted over time (0.3% per 
year) and none of the expected covariates were associated with this decline. This observed 
change was considerably less than the predicted average yearly decline that has been previously 
reported.14,15,34 For the first time in a cohort of children with SCA, we present lung function 
change over time in the context of the coefficient of variation, such that 78.7% of our cohort had 
an absolute change (increase or decrease) in lung function that exceeded the coefficient of 
variation for one or more lung function parameters.   
Our findings demonstrate a smaller decline in FEV1 % predicted per year when compared 
to other studies in children with SCA. In a retrospective analysis of 45 children with at least two 
spirometry measurements performed a minimum of a year apart, Koumbourlis et.al. showed a 
generally normal pattern of lung function but with a significant decrease in FEV1 % predicted 
from first to second measurement (87 +/- 21 vs. 80 +/- 15, p<0.001), with a decline over time of 
approximately 2% per year.34 A second retrospective study by MacLean et al. of 312 children 
and adolescents with SCA showed a significant decline in FEV1 % predicted of approximately 
3% per year, which was variable by sex and hemoglobin phenotype.14  In the only prior 
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prospective study, Lunt et al. demonstrated  a decline of 1.7% per year in one cohort and 0.9% 
per year in a second cohort.15 Findings of the prior SCA cohort studies evaluating FEV1 % 
predicted are summarized in Supplemental Table 4.   
The distribution of lung function categorization found in our cohort at baseline is similar 
to reports in other cohorts of children with SCA.15,34 While a change in lung function pattern was 
observed in some of our study population, this pattern was not significant or predictable over 
time. Our data suggest that the progression from normal to restrictive defects, may not begin in 
childhood.  
A critical component in interpreting longitudinal changes in FEV1% predicted in the 
current study and all previous studies, is the coefficient of variation. Unfortunately none of the 
prior three studies estimating FEV1 % predicated determined the CV. Our calculated CV for 
FEV1 % predicted in our population of children with SCA less than and greater than 16 years of 
age, was 7.32% and 4.46%, respectively showing more variation in the younger children 
compared to adolescents. The CV for FEV1 % for the group in total was 6.91%. Studies of 
healthy adult individuals, using a similar instrument, have reported a CV for FEV1 of 2.74%.
16 
Studies in adult asthma, CF, and chronic obstructive pulmonary disease (COPD) have reported 
larger CV of 3.77%,35 8.29%,35 and 3.60% 36  respectively. Our results appear to be within range 
of other chronic illnesses, with as expected clinically, more variation in the CV being observed 
in the younger population. For the subset of participants who did demonstrate a decline in FEV1 
% predicted larger than the CV, none of the postulated clinical covariates nor treatment with 
hydroxyurea were associated with this decline. Only individuals with a higher baseline FEV1 % 
predicted were more likely to show a significant decline greater than the CV and the result was 
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likely due to regression to the mean, caused by random variation in observed values around the 
true mean.37  
An unexpected finding in our cohort is the association of an increase in FVC % predicted 
(but not FEV1 % predicted) with hydroxyurea use shown in the multivariable model (2.02, 95% 
CI 0.04-4.0, p=0.05). However, this small change is well within the boundaries of the 95% 
confidence intervals of CV for FVC measured in this cohort( < 16 years of age: 6.21%, (5.56-
7.03%) age ≥ 16 years of age: 3.76%, (3.36-4.26%), raising the question as to  whether the 
measured increase in FVC% predicted  is random or clinically significant. None of the other 
three studies evaluating change in FVC demonstrated an increase in FVC% predicated. McLaren 
et al. demonstrated a decline an FEV1 and FVC over time with use of hydroxyurea; however, this 
decline was less in those on hydroxyurea when compared to those not on hydroxyurea.38  Further 
studies are needed to clarify the impact of hydroxyurea use on pulmonary function over time in 
children with SCA.   
Our study is limited in that all factors contributing to a decline in lung function over time 
may not have been assessed. Our analysis focused on what has been perceived as the most 
clinically relevant risk factors in SCA based on the available literature at the time of study entry. 
Additionally, while we followed a large number of participants, the mean duration was 
approximately 4 years and the mean age was 11 years. Quite possibly our participants were too 
young and followed for too short of a period of time to demonstrate a large change in lung 
function during the study period. Based on the substantial discrepancy between observed and 
expected FEV1 % predicted in adults with SCA, we postulate that there is a greater change in 
lung function occurring beyond the average age in our cohorts, 11.0 years, and below the age of 
the CSSCD and Vanderbilt- Meharry Sickle Center adult cohorts, 32 years. We hypothesize our 
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cohort simply did not have a sufficient long enough follow-up period to identify possible clinical 
risk factors that may result in significant decline in FEV1 % predicted observed in adults with 
SCA. Furthermore, as has been suggested in children with cystic fibrosis, conventional 
spirometry may not be the best tool to test for lung disease in children with SCA.39 Consideration 
should be given to predictors of lung disease such as lung clearance index and assessment of 
lung structure to truly capture early lung disease in children. 
In a large rigorously evaluated and prospective research cohort of children with SCA, 
FEV1 % predicted declined minimally over an average of 4 years and none of the SCA specific 
clinical characteristics, significantly predicted a decline in lung function. Additionally, we found 
that the small FEV1 % predicted decline in children was discrepant with the observed average 
FEV1 % predicted in two adult cohorts. New longitudinal studies that extend across the transition 
age group into adulthood and more refined pulmonary function assessment methods are needed 
to further explore the impact of sickle cell lung disease on pulmonary growth and function in 
young adults with SCA.   
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